A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Fasinumab (Primary) ; Naproxen
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT OA1
- Sponsors Regeneron Pharmaceuticals
- 17 Sep 2018 Planned number of patients changed from 2240 to 2845.
- 17 Sep 2018 Planned End Date changed from 30 Nov 2020 to 5 Apr 2021.
- 17 Sep 2018 Planned primary completion date changed from 22 Apr 2019 to 26 Aug 2019.